Atrium Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Atrium Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) has a cash flow conversion efficiency ratio of -0.093x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.25 Million) by net assets ($207.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Atrium Therapeutics, Inc. Common Stock (2018–2025)
Cash flow conversion efficiency of Atrium Therapeutics, Inc. Common Stock from 2018 to 2025. This chart illustrates how Atrium Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Atrium Therapeutics, Inc. Common Stock (RNA) stock price for real-time trading data and today's change.
Atrium Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Atrium Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Atrium Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrium Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see how much is Atrium Therapeutics, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nynomic AG
F:M7U
|
-0.045x |
|
YESASIA HOLDINGS LTD
F:4CM
|
N/A |
|
Basso Industry Corp
TW:1527
|
0.014x |
|
Suheung Capsul
KO:008490
|
0.017x |
|
Manulife Holdings Bhd
KLSE:1058
|
-0.011x |
|
Sajo Ind
KO:007160
|
-0.007x |
|
Heungkuk F&M I
KO:000540
|
0.097x |
|
MEDIFAST INC
NYSE:MED
|
0.009x |
Annual Cash Flow Conversion Efficiency for Atrium Therapeutics, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atrium Therapeutics, Inc. Common Stock from 2018 to 2025. Review Atrium Therapeutics, Inc. Common Stock (RNA) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $207.29 Million | $-41.13 Million | -0.198x | +6.03% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more